Skip to main content
. 2020 May 15;1(3):100052. doi: 10.1016/j.jtocrr.2020.100052

Table 2.

Patients Characteristics According to Different KRAS Point Mutations

Patients Characteristics G12C (N = 374) G12V (N = 168) G12D (N = 131) G12A (N = 62) G12S (N = 25) G12F (N = 11) G13C (N = 45) G13D (N = 31) Other (N = 44) Total (N = 901)
Sex
 Male
 N (%) 253 (67.6) 107 (63.7) 92 (70.2) 38 (61.3) 13 (52.0) 5 (45.5) 35 (77.8) 21 (67.7) 29 (65.9) 593 (66.6)
 Female
 N (%) 121 (32.4) 61 (36.3) 39 (29.8) 24 (38.7) 12 (48.0) 6 (54.5) 10 (22.2) 10 (32.3) 15 (34.1) 298 (33.4)
Age (years)
 Median 61.01 61.06 64.28 62.62 61.36 61.34 59.90 60.16 59.40 61.61
 Range 38.9–87.7 30.0–87.2 32.6–85.2 41.3–82.4 45.3–84.4 46.4–80.5 39.7–83.3 41.8–80.0] 39.3–82.5 30.0–87.7
Asian origin
 Yes
 N (%) 4 (1.2) 0 0 0 0 0 0 0 0 4 (0.4)
 No
 N (%) 329 (98.8) 152 (100.0) 115 (100.0) 57 (100.0) 21 (100.0) 9 (100.0) 38 (100.0) 26 (100.0) 40 (100.0) 787 (88.3)
 Missing
 N 41 16 16 5 4 2 7 5 4 100
Smoking
 Nonsmoker
 N (%) 12 (3.2) 9 (5.4) 19 (14.5) 1 (1.6) 0 0 1 (2.2) 0 0 42 (4.7)
 Smoker/former smoker
 N (%) 362 (96.8) 159 (94.6) 112 (85.5) 61 (98.4) 25 (100.0) 11 (100.0) 44 (97.8) 31 (100.0) 44 (100.0) 849 (95.3)
PS
 0–1
 N (%) 243 (68.3) 119 (73.0) 91 (71.7) 42 (71.2) 14 (63.6) 9 (81.8) 35 (83.3) 15 (55.6) 27 (65.9) 595 (66.8)
 2
 N (%) 84 (23.6) 36 (22.1) 27 (21.3) 13 (22.0) 5 (22.7) 1 (9.1) 7 (16.7) 12 (44.4) 12 (29.3) 197 (22.1)
 3–4
 N (%) 29 (8.1) 8 (4.9) 9 (7.1) 4 (6.8) 3 (13.6) 1 (9.1) 0 0 2 (4.9) 56 (6.3)
 Missing
 N 18 5 4 3 3 0 3 4 3 43
Histology
 Squamous
 N (%) 5 (1.3) 2 (1.2) 3 (2.3) 0 0 0 0 0 0 10 (1.1)
 Adenocarcinoma
 N (%) 310 (82.9) 135 (80.4) 104 (79.4) 54 (87.1) 20 (80.0) 8 (72.7) 40 (88.9) 26 (83.9) 37 (84.1) 734 (82.4)
 Large cell
 N (%) 8 (2.1) 8 (4.8) 2 (1.5) 1 (1.6) 0 0 2 (4.4) 2 (6.5) 3 (6.8) 26 (2.9)
 Other
 N (%) 51 (13.6) 23 (13.7) 22 (16.8) 7 (11.3) 5 (20.0) 3 (27.3) 3 (6.7) 3 (9.7) 4 (9.1) 121 (13.6)

PS, performance status.